Article
Neurosciences
Ye Yang, Yujun Long, Dongyu Kang, Chenchen Liu, Jingmei Xiao, Renrong Wu, Jingping Zhao
Summary: The study suggests that probiotics may reduce olanzapine-induced weight gain at the early stage of treatment and delay olanzapine-induced appetite increase. However, this difference disappears at 8 and 12 weeks of treatment.
PSYCHOPHARMACOLOGY
(2021)
Article
Nutrition & Dietetics
Marion E. C. Buso, Radhika V. Seimon, Sally McClintock, Roslyn Muirhead, Fiona S. Atkinson, Shannon Brodie, Jarron Dodds, Jessica Zibellini, Arpita Das, Anthony L. Wild-Taylor, Jessica Burk, Mikael Fogelholm, Anne Raben, Jennie C. Brand-Miller, Amanda Sainsbury
Summary: The study found that a higher-protein, low-GI diet for weight maintenance does not attenuate changes in ghrelin or peptide YY compared with a moderate-protein, moderate-GI diet. Subjective appetite sensations were not affected by the weight-reducing diet nor the weight-maintenance diets. While participants regained an average of similar to 50% of the weight they had lost by 36 months, the changes in ghrelin and peptide YY during the weight-reducing phase did not correlate with weight regain.
FRONTIERS IN NUTRITION
(2021)
Article
Nutrition & Dietetics
Catia Martins, Siren Nymo, Silvia R. Coutinho, Jens F. Rehfeld, Gary R. Hunter, Barbara A. Gower
Summary: The aim of this study was to determine the relationship between % FFML following weight loss and weight regain, as well as the association between % FFML and changes in appetite markers. The results showed that % FFML was not a significant predictor of weight regain at 1 year in individuals with obesity. However, a greater % FFML was associated with a greater increase in ghrelin secretion.
JOURNAL OF NUTRITION
(2023)
Article
Endocrinology & Metabolism
Nikolaos Perakakis, Olivia M. Farr, Christos S. Mantzoros
Summary: This study found that fasting levels of gastrointestinal hormones are associated with brain activity in response to highly desirable food stimuli in obese individuals. Specifically, GIP levels were inversely related to attention-related brain areas activation, while oxyntomodulin and glicentin levels were positively associated with reward-related brain areas activation.
DIABETES OBESITY & METABOLISM
(2021)
Article
Cell Biology
Shangang Zhao, Qian Lin, Wei Xiong, Li Li, Leon Straub, Dinghong Zhang, Rizaldy Zapata, Qingzhang Zhu, Xue-Nan Sun, Zhuzhen Zhang, Jan-Bernd Funcke, Chao Li, Shiuhwei Chen, Yi Zhu, Nisi Jiang, Guannan Li, Ziying Xu, Steven C. Wyler, May-Yun Wang, Juli Bai, Xianlin Han, Christine M. Kusminski, Ningyan Zhang, Zhiqiang An, Joel K. Elmquist, Olivia Osborn, Chen Liu, Philipp E. Scherer
Summary: Antipsychotic drugs can cause weight gain and diabetes, and hyperleptinemia plays a key role. Suppression of leptin rise can reduce the adverse effects of these drugs.
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Article
Psychiatry
Yuying Qiu, Yeqing Dong, Wei Sun, Gang Li, Mei Juan Li, Yongping Zhao, Changyong Jiang, Jie Li
Summary: In this study, potential biomarkers of risperidone-induced weight gain were identified using a targeted metabolomics approach. The results suggest that phosphatidylcholines and amino acids may serve as biomarkers for risperidone-induced weight gain.
FRONTIERS IN PSYCHIATRY
(2023)
Article
Pharmacology & Pharmacy
Sue Youn Kim, Jae Moon Yun, Ji-Won Lee, Young Gyu Cho, Kyung-Hwan Cho, Yong Gyu Park, Belong Cho
Summary: This study evaluated the efficacy and tolerability of cyproheptadine in adults with poor appetite in South Korea, showing that cyproheptadine significantly increased appetite, weight, and body mass index in patients. The drug was well tolerated, with somnolence being the most common adverse event.
CLINICAL THERAPEUTICS
(2021)
Review
Endocrinology & Metabolism
Marthe Isaksen Aukan, Silvia Coutinho, Sindre Andre Pedersen, Melanie Rae Simpson, Catia Martins
Summary: This systematic review and meta-analysis investigated the differences in gastrointestinal hormone response to food intake between individuals with and without obesity. The findings suggest that individuals with obesity have lower concentrations of total ghrelin and total peptide YY compared to controls, which may contribute to lower postprandial hunger ratings. However, there were no significant differences in other gastrointestinal hormones or appetite ratings. The study highlights the need for more comprehensive research to determine if these differences are a cause or consequence of obesity.
Article
Endocrinology & Metabolism
Ozgur Korhan Tuncel, Zuhal Altunkaynak, Birsen Bilgici, Arzu Karaustaoglu, Taner Ilker Gumrukcuoglu
Summary: This study found that the main cause of weight gain in the use of olanzapine was the increase in the number of hypothalamic ghrelin receptors. Investigating the mechanism by which olanzapine increases the number of ghrelin receptors may help to develop effective treatment strategies in preventing obesity in psychiatric patients.
PSYCHONEUROENDOCRINOLOGY
(2022)
Article
Pharmacology & Pharmacy
Georgios Schoretsanitis, Celine Dubath, Claire Grosu, Marianna Piras, Nermine Laaboub, Setareh Ranjbar, Nicolas Ansermot, Severine Crettol, Frederik Vandenberghe, Franziska Gamma, Armin Gunten, Kerstin Jessica Plessen, Erich Seifritz, Philippe Conus, Chin B. Eap
Summary: This study assessed the effects of olanzapine on metabolic parameters, and found that high-dose olanzapine treatment may lead to early weight gain, while low-dose treatment is associated with increases in blood lipids and blood pressure. Treatment duration and co-prescription of other medications were also found to be related to weight gain.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
(2022)
Article
Nutrition & Dietetics
Mette Glavind Billow Pedersen, Esben Stistrup Lauritzen, Mads Vandsted Svart, Julie Stoy, Esben Sondergaard, Henrik Holm Thomsen, Ulla Kampmann, Mette Bjerre, Niels Jessen, Niels Moller, Nikolaj Rittig
Summary: LEAP2 concentration decreases after fasting and increases postprandially. Oral administration of glucose and lactate elevates LEAP2 concentration, while BHB reduces LEAP2 concentration.
AMERICAN JOURNAL OF CLINICAL NUTRITION
(2023)
Article
Endocrinology & Metabolism
Susanna Bianzano, Andrea Henrich, Lena Herich, Brigitte Kalsch, Donald Sarubbi, Friedeborg Seitz, Thomas Forst
Summary: Two Phase I studies showed that BI 1356225, a GOAT inhibitor, was well-tolerated in healthy males and subjects with overweight/obesity. However, treatment with BI 1356225 for 28 days did not lead to significant reduction in bodyweight or changes in appetite, eating control, or energy intake.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2023)
Article
Pharmacology & Pharmacy
Ghulam Md Ashraf, Badrah S. Alghamdi, Fahad S. Alshehri, Mohammad Zubair Alam, Haythum O. Tayeb, Frank Tarazi
Summary: The study found that the antidiabetic drug EMPA effectively attenuated the body weight gain induced by the atypical antipsychotic drug Ola in female Wistar rats. The impact of Ola on female Wistar rats was significantly different from male rats, indicating a potential gender difference in body weight gain caused by antipsychotic drugs.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Nutrition & Dietetics
Nicole Fearnbach, Amanda E. Staiano, Neil M. Johannsen, Daniel S. Hsia, Robbie A. Beyl, Owen T. Carmichael, Corby K. Martin
Summary: Exercise may impact energy intake in adolescents by influencing appetite states rather than traits. Additionally, baseline energy intake after exercise is associated with weight change over time, indicating that appetitive cues play a significant role in post-exercise energy intake.
Review
Biochemistry & Molecular Biology
Chihiro Yamada
Summary: Stress plays a significant role in affecting appetite by modulating peptides involved in appetite regulation. The orexigenic peptide ghrelin is known to be crucial in appetite abnormalities in various diseases and psychological states. Studies have also shown the impact of sex differences and age on appetite under stress.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)